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ABSTRACT 
Sumatripatan succinate (SS) is a 5-HT1D agonist used in migraine therapy. Its low oral bioavailability (~15 %) is due to extensive pre-systemic 
metabolism and low biological half-life. The frequent administration of SS is required to maintain effective plasma concentration. In the present 
investigation, polymeric nanoparticles of SS (SS-NPs) were prepared by W1/O/W2 double emulsion solvent evaporation method followed by 
probe sonication. Poly-(lactide-co-glycolide) (PLGA) and poloxamer 188 were used as polymer and surfactant respectively to formulate SS-NPs. 
The particle size, polydispersity index, zeta potential, percent entrapment efficiency of SS-NPs were found to be 126 nm, 0.06, (-) 24.1 mV, 32.52 
± 2.34 % respectively. Characterization of lyophilized SS-NPs revealed formation of drug entrapped amorphous SS-NPs. Ex-vivo skin permeation 
studies of SS were conducted using distilled water, ethanol (EtOH), propylene glycol (PG) and their binary combinations. The lag time, flux, 
permeability and steady state permeability coefficient and enhancement ratio were determined. The ex-vivo permeation profiles of SS in 
different solvent systems were compared with SS-NPs in distilled water. The maximum flux of 345.8 µg.cm-2.h-1 was obtained with solvent 
system comprising 33% PG in EtOH. The minimum lag time and a comparable flux value was obtained in ex-vivo diffusion studies of SS-NPs. 
Hence, it can be concluded that SS-NPs can be administered in transdermal drug delivery system using a solvent system comprising 33%PG in 
EtOH. The present investigation indicated that using suitable solvent system and PLGA nanoparticles, the skin permeation of SS can be 
enhanced.  
Keywords: Migraine, sumatriptan succinate, poly-(lactide-co-glycolide), nanoparticles, transdermal patch 
 
Article Info: Received 09 June 2019;     Review Completed 19 July 2019;     Accepted 20 July 2019;     Available online 15 August 2019  
Cite this article as: 
Salve PS, Gupta RR, Ex-vivo skin permeation studies of sumatriptan succinate using different solvent systems and its 
comparison with PLGA nanoparticles , Journal of Drug Delivery and Therapeutics. 2019; 9(4-s):59-67  
http://dx.doi.org/10.22270/jddt.v9i4-s.3247                                               
*Address for Correspondence:  
Pramod Shridhar Salve, Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Mahatma Jyotiba Fuley 
Shaikshanik Parisar, Amravati Road, Nagpur-440 033, Maharashtra, India 
 
INTRODUCTION 
A migraine is a headache disorder affects approximately 15% 
of females and 6% of males. It is a neurobiological syndrome 
and the symptoms are unilateral throbbing 
headache. (George M 2006). A decreased level of 
vasoconstrictor amine 5-hydroxytryptamine vasodilates 
blood vessels of brain resulting in severe headache (Villalón 
CM 2003). Sumatriptan succinate (SS) is a serotonin agonist 
used in migraine therapy. SS is incompletely absorbed and 
undergoes pre-systemic metabolism. It therefore has a low 
oral bioavailability of about 15%. It exhibits a plasma half-
life and elimination half-life of approximately 1.5 h and 2.5 h 
respectively (SC Jagdale 2014, Ebell MH 2006). Sumatriptan 
Succinate is freely soluble in water (US EPA 2009) having 
molecular weight 413.489 (g/mol) and log P value 0.93.  
The mechanism of action of SS is vasoconstriction of 
meningeal arteries, inhibition of release of neurotransmitters 
from neurons in brain, prevention of the nociceptive 
transmission and reduction of the activity of trigeminal 
nerves (Hilaire 2004; Kolev 2007; Levy 2004; Silberstein 
2000). SS is hydrophilic in nature and has been reported to 
cross the blood brain barrier (BBB) to certain extent (Tfelt-
Hansen 2010). 
The serotonin receptor (5-hydroxytryptamine [5-HT]) is 
believed to be the most important receptor in the headache 
pathway. Immunohistochemical studies have detected 5-
hydroxytryptamine–1D (5-HT1D) receptors in trigeminal 
sensory neurons, including peripheral projections to the 
dura and within the trigeminal nucleus caudalis (TNC) and 
solitary tract, while 5-HT1B receptors are present on smooth 
muscle cells in meningeal vessels; however, both can be 
found in both tissues to some extent and even in coronary 
vessels.  
All the currently available triptans are selective 5-HT1B/D 
full agonists. These agents may decrease headache by 
abolishing neuropeptide release in the periphery and 
blocking neurotransmission by acting on second-order 
neurons in the trigeminocervical complex. 
The new techniques are required for crossing the blood 
brain barrier. The lipid soluble small molecules with 
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molecular weight less than 400 Da are able to cross the blood 
brain barrier via lipid-mediated free diffusion. Barrier layers 
are found at three main sites in the brain and spinal cord: the 
endothelium of parenchymal micro vessels, the epithelium of 
the choroid plexus secreting cerebrospinal fluid and 
arachnoid epithelium, the middle layer of the meninges 
forming the outer covering of the CNS (Abbott 2004a; Abbott 
et al 2010). At each of these sites, tight junctions significantly 
reduce permeation of ions and other small hydrophilic 
solutes through the intercellular cleft (Candela P 2010). 
Nanoparticles open tight junctions between endothelial cells 
resulting in penetration of free form of drug through BBB 
(X. Gao 2014, C.H.J. Choi 2010). Nanoparticulate drug 
delivery systems have been developed as an effective 
strategy for circumventing this barrier and targeting of drugs 
to the brain for better therapeutic efficacy (J. Kreuter 2001, 
2002). 
Poly (lactic-co-glycolic) acid (PLGA) is biocompatible 
biodegradable polymeric material and is approved for 
clinical use in humans by the U.S. Food and Drug 
Administration. PLGA has the potential to modify surface 
properties to provide better interaction with biological 
materials (Piergiorgio Gentile 2014). Transdermal drug 
delivery system (TDDS) avoids hepatic first pass metabolism 
of drug. Drug loaded polymeric nanoparticles can be 
administered by transdermal drug delivery system. TDDS 
maintains constant plasma levels of drug and enhances 
patient compliance by avoiding repeated administration of 
drug. The solvent system selection is important step in 
development of transdermal administration of drug as it 
affects the permeation of drug across skin by altering the 
barrier property of skin. In the view of physicochemical 
properties of SS, we envisaged to develop polymeric poly 
(lactic-co-glycolic) acid (PLGA) nanoparticles of SS (SS-NPs) 
and study the effect of solvent systems on ex-vivo permeation 
of SS and SS-NPs.  
MATERIALS AND METHOD 
Materials 
Sumatriptan succinate (SS) was received as a gift sample 
from Natco Pharma Limited,  Hyderabad, India. Purasorb 
PDLG 5002A was received as a gift sample from Corbion 
Purac Biomaterials, Netherlands, and U.S.A. Pluronic F-68 
was received as gratis sample from BASF, Mumbai. Distilled 
water used for the preparation and processing purposes was 
double distilled water (Bio-Age, Direct Ultra TUVF5, Punjab, 
India).  
All other chemical and reagents used during studies were of 
suitable analytical grade and were used as received. 
Methods 
Preparation of sumatriptan succinate polymeric 
nanoparticles (SS-NPs) 
The PLGA polymeric nanoparticles containing sumatripatan 
succinate were prepared by double emulsion solvent 
evaporation technique (Ipek Baysal, 2013). The composition 
of formulation batches are shown in table 1. An accurately 
weighed amount of SS (5 mg) was dissolved in 2 mL distilled 
water to form aqueous phase (W1). It was added drop wise 
into organic phase (O) consisting of PLGA dissolved in 
dichloromethane (5 mL) and mixed well using a magnetic 
stirrer (Labman Scientific Instruments, India) at speed of 
800 rpm to form primary emulsion (W1/O). The primary 
emulsion was further added drop wise with the help of 
syringe into aqueous phase (W2) consisting of 15 mL 
Pluronic F 68 in 1 and 2 %w/v as a stabilizer and 
homogenized using a high speed homogenizer (IKA Ultra 
turrex T18, Germany) at speed 12,000 rpm followed by 
probe sonication (Sonics Vibra Cell ™) at 80 % amplitude for 
5 min. Organic solvent was evaporated under continuous 
magnetic stirring at room temperature. The polymeric 
nanoparticles were recovered by refrigerated centrifugation 
at 20,000 rpm for 60 min at 15 ℃, washed with distilled 
water to remove additives.  
A cryoprotectant solution comprising 5 %w/v mannitol was 
added to nanoparticle pellet formed after centrifugation. It 
was vortexed (Impact, Icon Instruments Company, India) 
followed by bath sonication (PCi, India) for 5 min and filled 
in glass vials. The vials were freeze dried at (-) 40 °C and 850 
mm/Hg vacuum for 72 h using a lyophilizer (Mac ®, Macro 
Scientific Works, India) and stored in refrigerator in airtight 
glass container sealed with parafilm.  
Experimental procedure was repeated with varied drug and 
polymer ratios and surfactant concentrations. 
 
Table 1 Compositions of SS-NP formulations  
Screening Parameter 
Parameter 
Formulationses 
PNP1 PNP2 PNP3 PNP4 PNP5 PNP6 
SS : PLGA ratio 
SS (5 mg/2 mL) 
1:3 
(5:15) 
1:3 
(5:15) 
1:3 
(5:15) 
1:3 
(5:15) 
1:5 
(5:5) 
1:5 
(5:25) 
Solvent (5 mL) DCM DCM DCM DCM DCM DCM 
Surfactant 
(15 mL) 
Pluronic 
F68 
Pluronic 
F68 
Pluronic 
F68 
Pluronic 
F68 
Pluronic 
F68 
Pluronic F68 
Concentration of 
surfactant (%w/v) 
1 1 1 2 2 2 
PNP = Polymeric nanoparticle, DCM = Dichloromethane 
 
Characterization of the SS-NPs 
Percent entrapment efficiency and percent drug loading 
The nanoparticle suspension was subjected to centrifugation 
at 20,000 rpm for 30 min. at 15 ℃. Percent percent 
entrapment efficiency (% EE) was assessed using equation 1 
(Deepti Mittal, 2014). Polymeric nanoparticle pellet was 
dissolved in specified volume of ethyl acetate and shaken for 
4 h. Drug was extracted into equal quantity of water. This 
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solution was filtered to remove insoluble fractions of 
polymer and amount of drug was determined at 227 nm. 
         Total drug content − Amount of free drug in supernatant  
% EE =                                                                                                        × 100   
                    Total drug content 
 Physicochemical characterization of SS-NPs 
For determination of mean particle size of SS-NPs, 5 mg 
sample of SS-NPs was dispersed in 10 mL deionized water. 
The mean particle size, polydispersity index and zeta 
potential were determined using Zetasizer Nano ZS 90 
(Malvern Instruments, UK) (Wissing SA, 2004).  
 The surface morphology and structure of lyophilized SS-NPs 
were visualized by scanning electron microscopy (Zeiss SEM 
EVO-18, Carl Zeiss Microscopy). Water re-suspended 
nanoparticles were mounted on a glass slide as a thin smear 
and left to dry. The particles on the dried glass slide were 
subjected to gold sputtering and slide was attached on SEM 
holder using a double side carbon tape mounted on 
aluminium stud. The SEM photomicrographs were captured 
by operating at an accelerating voltage of 20 kV electron 
beam at desired magnification (Sharma G, 2015). 
Characterization of lyophilized SS-NPs 
Fourier Transform Infrared (FT-IR) Spectroscopy 
The sample of lyophilized SS-NPs of was triturated and 
mixed well with IR grade potassium bromide in 1:100 ratio 
and the mixture was introduced in sample holder of FT-IR 
instrument (IRAffinity-1, Shimadzu, Japan) and scanned in 
the range 4000 to 400 cm-1. The obtained spectrum was 
compared with the spectrum of SS and PLGA (Shu-Ben Sun, 
2015). 
Differential scanning calorimetry (DSC) 
A sample of lyophilized SS-NPs was kept in desiccator for 24 
h before thermal analysis. An accurately weighed 5 mg 
sample was hermetically sealed in aluminium crucible and 
heated at constant rate of 10 ℃ / min over a temperature 
range 40 to 300 ℃ using DSC (TA Instruments Trios V4.1). 
An inert atmosphere was maintained by purging nitrogen 
gas at a flow rate of 50 mL/min. An empty aluminium pan 
was used as a reference. The thermogram obtained was 
compared with the thermograms of SS and PLGA (Shu-Ben 
Sun, 2015). 
X-ray diffraction (XRD) spectroscopy 
X-ray diffraction spectrum of lyophilized SS-NPs was 
recorded by instrument (Brucker AXS D8 Advance, Germany) 
using Cu-Kα line as source of radiation at a voltage of 35 kV 
and current 25 mA. The sample was measured in 2θ angle 
range between 3-80⁰and 0.0053 step size. The diffraction 
spectrum obtained was compared with the diffraction 
spectrum of SS and PLGA (Adeyinka Aina, 2016). 
Ex-vivo skin permeation studies  
Preparation of whole skin 
Ex-vivo skin permeation studies were conducted to evaluate 
the effects of various vehicles (ethanol, propylene glycol and 
their binary combinations) on permeability profiles of SS. 
The permeability profile of SS-NPs. For preparation of whole 
skin, the animal was sacrificed by excess inhalation method. 
The dorsal skin of animal was shaved with the help of animal 
hair clipper in the direction of tail to head without causing 
damage to skin. The shaved skin was excised with the help of 
surgical blade (size 24) fitted in a surgical blade holder (size 
4). The adhered tissues to the dermis was removed with the 
help of scalpel blade. The adhering fat to the dermis was also 
removed by cleaning with cotton swab moistened with 
isopropyl alcohol. The skin was washed with distilled water, 
wrapped in aluminum foil and stored in freezer at (-)200C till 
further use. The skin was thawed to room temperature. The 
skin was kept in thermostatic shaker bath at 37±1 0C 
temperature for 1 h. The receptor fluid containing 0.01% of 
sodium azide was sonicated for 15 min and filled in the 
receptor compartments and equilibrated to bring it to 37 0C 
temperature. The skin was cut into circular pieces to a size of 
external circumference of donor compartment and mounted 
on diffusion cell assembly, keeping Stratum corneum side 
towards donor compartment and equilibrated for one hour. 
From the receptor phase, 1 ml volume was withdrawn to 
check for the amount of drug present if any from previous 
experiment. The 2 ml of drug solution (40 mg) was applied in 
donor compartment. From the receptor compartment, 1 ml 
volume was withdrawn at 0,1,2,4,6,8,10,12, 16,20,24, 36, 48, 
60, and 72 h and replaced with equal volume of fresh 
receptor phase every time.  The withdrawn sample was 
analyzed for drug content. The lag time, flux, permeability, 
and enhancement ratio were calculated. Cartesian plots were 
made, taking time in hours on X-axis and cumulative amount 
of drug present in receptor fluid on Y-axis. Flux values 
(mg/cm2.h) were calculated from the slopes of the steady 
states of above plots. Lag times were calculated from the 
intercepts of extrapolated steady state flux to X-axis. 
Permeability values were calculated by following equation 1 
(Panchagnula 2001).                        
                                           Steady State Flux 
Permeability =      
                            Concentration of drug in donor solution            
RESULTS AND DISCUSSION 
Preparation of sumatriptan succinate nanoparticles (SS-
NPs) 
The polymeric nanoparticles containing sumatriptan 
succinate were prepared.  A total six formulations with 
varying SS and PLGA ratios and varying Pluronic F-68 
concentrations were developed and characterized for 
particle size, polydispersity index and zeta potential. 
Characterization of SS-NPs 
Percent entrapment efficiency and percent drug loading 
The formulations PNP 1, PNP 2 and PNP 3 were found to be 
unstable. The entrapment efficiency in formulations PNP 1, 
PNP 2 and PNP 3 was found to be low as compared to 
formulation PNP4. The entrapment efficiency of formulation 
PNP 4 was found to be 32.52±2.34 %.  
Particle size and Zeta Potential 
The particle size (nm) and polydispersity index (PDI) of SS-
NPs (Formulations PNP 4, PNP 5 and PNP 6) were found to 
be 126.0 nm, 281.8 nm, 188.0 nm and 0.060, 0.700, 0.378 
respectively. The formulation containing 1:3 ratio of SS: 
PLGA with 2 (%w/v Pluronic F68 has shown the minimum 
particle size 126 nm with PDI value 0.060 (Ostertag F, 2012). 
The zeta potential (mV) of SS-NPs (formulations PNP 4, PNP 
5 and PNP 6) were found to be (-) 24.1 mV, (-) 18.4 mV and (-
) 12.1 mV respectively (Upadhyay S, 2012). Based on the 
values of % EE, % DL, particle size, PDI and zeta potential, 
PNP 4 was found to be optimized SS-NPs formulation (Figure 
1). 
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Figure 1 Graphs of particle size and PDI (a,c,e) Graphs of zeta potential (b,d,f) of formulations PNP 4, PNP 5,  PNP 6 
Drug-polymer interaction studies  
FT-IR Spectroscopy 
FT-IR spectra of the SS, PLGA and lyophilized SS-NPs are 
shown in figure 2,3 and 4 respectively. In comparison to the 
FT-IR spectrum of SS, the lyophilized SS-NPs exhibited 
disappearance of characteristic peaks and broadening of few 
peaks with reduction in intensity. The peak broadening 
phenomenon with hump in the FT-IR spectrum of 
lyophilized nanoparticles indicated formation of polymeric 
nanoparticles.
 
 
Figure 2 FT-IR spectrum of sumatriptan succinate 
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Figure 3 FT-IR spectrum of PLGA polymer 
 
 
Figure 4 FT-IR Spectrum of lyophilized SS-NPs formulation batch PNP 4 
 
Differential scanning calorimetry (DSC)  
The DSC thermograms of SS, PLGA and lyophilized SS-NPs 
are shown in Figure 5,6, and 7 respectively .In comparison to 
the DSC thermogram of SS and PLGA, thermogram of 
lyophilized nanoparticles showed splitting of thermogram at 
157.29 ℃ and 167.64 ℃ with enthalpy values 28.490 J/g and 
46.285 J/g. The shifting of melting endotherm from 171.26 
℃ to 167.64 ℃ with reduction in the enthalpy from 141.48 
J/g to 28.(SS-NPs) 490 J/g indicated the formation of 
nanoparticles. Also, the enthalpy of polymer was also found 
to significantly decreased from 804.47 J/g to 46.285 J/g 
indicating that energy has been utilized in the entrapment of 
SS within the formed polymeric nanoparticles. An endotherm 
at 167.64 ℃ signified the presence of free amount of drug on 
surface of SS-NPs.  
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Figure 5 DSC thermogram of sumatriptan succinate 
 
Figure 6 DSC thermogram of PLGA polymer 
 
Figure 7 DSC thermogram of lyophilized SS-NPs formulation batch PNP 4 
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X-ray diffraction (XRD) spectroscopy 
The XRD pattern of SS, PLGA and lyophilized SS-NPs are 
shown in figure 8,9 and 10 respectively. The diffraction 
pattern of lyophilized SS-NPs showed reduction in the 
number and intensity of peaks when compared with the 
spectrum of the SS and PLGA. The diffraction pattern of PLGA 
has shown complete absence of peaks at an angle 2θ 
indicating the amorphous nature of polymer. The peaks 
observed in XRD pattern at an angle 2θ of SS were 15.42, 
16.22, 16.40. These peaks were found to be absent in XRD 
pattern of lyophilized SS-NPs and new peaks at 9.87, 17.47 
were observed. A decrease in crystalline characteristic of SS 
and formation of partial amorphous characteristic of 
lyophilized SS-NPs was observed in XRD studies. 
 
 
 
Figure 8 X-ray diffraction spectrum of SS 
 
Figure 9 X-ray diffraction spectrum of PLGA polymer 
 
Figure 10 X-ray diffraction spectrum of lyophilized SS-NPs (formulation PNP 4) 
 
Ex-vivo skin permeation studies 
The ex-vivo skin permeation studies of sumatriptan 
succinate and sumatriptan succinate loaded polymeric 
nanoparticles (SS-NPs) were conducted using distilled 
water, ethanol, propylene glycol and their binary 
combinations. The ex-vivo permeation studies of SS 
conducted using distilled water were treated as control 
(group 1). The lag time, flux, permeability, steady state 
permeability coefficient and enhancement ratio were 
determined (Table 2).  
The lag time in control group with water as solvent was 
found to be maximum as compared to the other solvent 
systems studied. The polymeric nanoparticles of 
sumatripatan succinate (SS-NPs) demonstrated minimum 
lag time of 6 h as compared to the control group and solvent 
systems studied. With increasing concentration of ethanol in 
water as observed in group S3 S4, S5, the lag time was found 
to be increased. It is due to stabilization and rigidization of 
intercellular lipids of stratum corneum membrane of skin 
hindering the passage of drug across the skin. No significant 
change in lag time was observed with increase in PG 
concentration in water (treatment group S6, and S7). 
However, with further enhancing of concentration of PG to 
100%, the lag time was found to be slightly increased group 
S8). It is due to hygroscopic characteristic of PG which 
extracts water from bilayer lipids, increases tortuosity and 
diffusional path length for permeation of drug resulting in 
enhanced lag time. With PG and ethanol binary solvent 
system studied, the lag time was found to be decreased in 
group S9 to S10 and no change in lag time was observed in 
group S11. It is due to the thermodynamic activity of PG and 
ethanol on stratum corneum.  
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In the ex-vivo skin permeation studies of the polymeric 
nanoparticles of sumatritan succinate (SS-NPs) (group 2) in 
distilled water as solvent has shown an enhanced flux values 
as compared to permeation of control group. Also, the lag 
time was significantly decreased as compared to the control 
group. The enhanced permeation of SS-NPS was due to their 
small size in nonometer range which allowed for better 
penetration across the stratum corneum membrane 
In group S3, S4, and S5, flux values of SS were found to 
increase proportionately with an increase in ethanol 
concentration in water from 33 to 66%. A significant 
increase in flux values were observed in ethanol treated 
groups as compared to control group. Ethanol exerts 
concentration dependent effect on the stratum corneum 
(Berner et al. 1989). The effect of ethanol on skin occurs by 
two mechanisms namely push effect whereby the 
evaporation of ethanol increases thermodynamic activity. 
(Kadir et al. 1987). The other mechanism exists whereby 
ethanol increases permeation of drug across skin due to 
reduction in barrier property of stratum corneum of skin. At 
lower concentration, ethanol exerts effect on lipoidal 
pathway while at higher ethanol concentration, effect on 
intercellular lipids as well as effect on polar pathway occurs. 
  The group S6, S7, the increasing concentration of PG in 
water has shown increase in flux values from 33 to 66%, 
while the formulation S8 containing 100% PG, a reduction in 
flux values was observed. A significant increase in flux 
values were observed in PG treated groups as compared to 
control group. PG exerts its effect as permeation enhancer 
effect due to its co-solvency effect. The thermodynamic 
activity of SS might have been increased due to effect of PG. 
The enhanced thermodynamic activity is the driving force 
for the permeation of SS across stratum corneum layer of 
skin. PG exerts its penetration enhancer effect by the carrier 
mechanism. The partitioning of PG into skin creates the 
movement of drug into the skin. At higher PG concentration 
(100%), the water present in the skin is drastically reduced 
hindering the movement of SS into skin resulting into 
decreased flux values. The hygroscopic property of PG takes 
water from binary combination with water. At higher 
concentration, PG takes water from skin lipids and 
corneocytes and complete dehydration of stratum corneum 
occurs resulting in increased barrier property of skin. 
Propylene glycol may also form a pool in the bilayer lipids 
hindering the passage of drug.  
In group S9 containing 33% PG in ethanol, maximum flux 
was observed. It is due to thermodymanic activity of both PG 
and ethanol on epidermis. The decreased barrier property 
due to action of PG and EtOH on stratum corneum of skin 
has resulted in flux value. With increase in PG concentration 
as in group S10, the flux value was found to be decreased as 
compared to group S9. It is due to the dehydration effect of 
PG. In group S11, the flux value was increased as compared 
to group 10. It is due to co-solvency and partitioning effect of 
PG.  
From the solvent systems studied for the ex-vivo permeation 
of sumatriptan succinate, the maximum flux values were 
obtained with solvent system comprising ethanol: PG in 
33.5:66.5 ratio. The reduction in barrier property of stratum 
corneum and increased thermodynamic activity are the 
probable reasons for the highest flux of SS across skin. The 
flux of SS-NPs was found to be decreased as compared to 
flux value of SS with solvent system ethanol: PG in 33.5:66.5 
ratio. However, the minimum lag time was observed with SS-
NPs. Hence, it can be concluded that the SS-NPs can be 
administered with solvent system ethanol: PG in 33.5: 66.5 
ratio for obtaining better control on lag time and flux values.
 
Table 2 Ex-vivo skin permeation parameters of sumatriptan succinate and its polymeric nanoparticles in various solvent 
systems 
Sr. 
No. 
Group 
code 
Solvent 
System 
Lag 
time 
(h) 
Flux 
(µg/cm2/h) 
Permeability 
(=Slope/Concentration 
of drug in donor 
compartment) 
Steady state 
permeability 
coefficient(Kp) 
(cm/h) 
Enhancement ratio 
ER = (Kp of SS-NPs) / 
(Kp of drug) 
 
1 S1 Control 20 140.4 3.15 89.42 0 
2 S2 SS-NPs 6 331.8 8.29 211.33 2.36 
3 S3 33% EtOH 
in Water   
8 264.0 6.6 168.15 1.88 
5 S4 50% EtOH 
in Water   
13 286.9 7.17 182.73 2.04 
6 S5 66% EtOH 
in Water   
16 310.7 7.76 197.89 2.21 
7 S6 33% PG in 
Water   
9 189.3 4.73 120.57 1.34 
8 S7 66% PG   
in water   
8 209.3 5.23 133.31 1.49 
9 S8 100% PG 10 199.7 4.99 127.19 1.42 
10 S9 33 % PG in 
EtOH  
12 345.8 8.64 220.25 2.46 
11 S10 50% PG in 
EtOH  
10 317.7 7.94 202.35 2.26 
12 S11 66% PG in 
EtOH  
10 336.2 8.40 214.14 2.39 
 
CONCLUSION 
The low oral bioavailability of sumatripatan succinate is due 
to extensive hepatic first pass metabolism metabolism and 
low biological half-life. The frequent administration of SS is 
required to maintain effective plasma concentration. 
Polymeric nanoparticles of SS (SS-NPs) were prepared by 
W1/O/W2 double emulsion solvent evaporation method 
followed by probe sonication. Poly-(lactide-co-glycolide) 
(PLGA) and poloxamer 188 were used as polymer and 
surfactant respectively to formulate SS-NPs. The particle 
size, polydispersity index, zeta potential, percent 
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entrapment efficiency of SS-NPs were found to be within 
acceptable range. Characterization of lyophilized SS-NPs by 
differential scanning calorimetry, FT-IR spectroscopy and X-
ray diffraction spectroscopy revealed formation of drug 
entrapped amorphous SS-NPs. Ex-vivo skin permeation 
studies of SS were conducted using distilled water, ethanol 
(EtOH), propylene glycol (PG), and their binary 
combinations. The solvent system comprising 33% PG in 
EtOH was found to be the optimum solvent system for 
transdermal drug delivery of sumatriptan succinate. The 
minimum lag time and a comparable flux value was obtained 
in ex-vivo permeation studies of SS-NPs. Hence, it can be 
concluded that SS-NPs can be administered in transdermal 
drug delivery system using a solvent system comprising 
33%PG in ethanol. The present investigation indicated that 
using suitable solvent system and PLGA nanoparticles, the 
skin permeation of sumatriptan succinate can be enhanced.  
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